コンテンツへスキップ
Merck

350R-1

Sigma-Aldrich

FoxP1 (SP133) Rabbit Monoclonal Antibody

ログイン組織・契約価格を表示する


About This Item

UNSPSCコード:
12352203
NACRES:
NA.41

由来生物

rabbit

品質水準

100
500

結合体

unconjugated

抗体製品の状態

culture supernatant

抗体製品タイプ

primary antibodies

クローン

SP133, monoclonal

詳細

For In Vitro Diagnostic Use in Select Regions (See Chart)

フォーム

buffered aqueous solution

化学種の反応性

human

包装

vial of 0.1 mL concentrate (350R-14)
vial of 0.5 mL concentrate (350R-15)
bottle of 1.0 mL predilute (350R-17)
vial of 1.0 mL concentrate (350R-16)
bottle of 7.0 mL predilute (350R-18)

メーカー/製品名

Cell Marque

テクニック

immunohistochemistry (formalin-fixed, paraffin-embedded sections): 1:100-1:500

アイソタイプ

IgG

コントロール

DLBCL, lymph node, tonsil

輸送温度

wet ice

保管温度

2-8°C

視覚化

nuclear

遺伝子情報

human ... FOXP1(27086)

詳細

Diffuse large B-cell lymphoma (DLBCL) represents different clinicopathologic entities which are difficult to separate using standard techniques. From the clinical standpoint, the introduction of immunochemotherapy in the treatment of DLBCL has dramatically improved the outcome of these patients compared with chemotherapy alone. Gene expression profiling (GEP) studies have shown that DLBCL can be reproducibly divided into the important subtypes of germinal center B-cell–like (GCB), activated B-cell–like (ABC), and unclassified DLBCL. It is beneficial to translate the GEP classification into protein expression by tumor cells through immunohistochemical (IHC) staining of formalin-fixed, paraffin-embedded tissues. A panel of antibodies: CD10, BCL6, MUM1/IRF4, GCET1, FoxP1, LMO2, and BCL2 has been used to determine GCB or ABC and each has different percentage thresholds for positive staining. Choi et al. demonstrated that the cases positive for GCET1 (≥ 80% of tumor cells) and MUM1/IRF4 (≥ 80%) and/or FoxP1 (≥ 80%) or negative for CD10 and BCL6 (≤ 30%) were assigned to the group. The cases positive for CD10 (≥ 30%), GCET1 (≥ 80%) without MUM1 expression, or positive for BCL6 without FoxP1 expression were classified as GCB. This study indicated the importance of FoxP1 in the subclassification of DLBCL. Choi et al then modified their approach to DLBCL subclassification by focusing on FoxP1. The tumors that are positive for both FoxP1 and GCET1 are assigned to GCB subgroup, but, if FoxP1 is positive and GCET1 is negative, the tumors belong to the ABC phenotype. If a case is FoxP1 negative but MUM-1/IRF4 positive, it still belongs to the ABC phenotype as long as CD10 is not expressed. This modified method emphasized the role of FoxP1, MUM1/IRF4, and GCET1 in the subclassification of DLBCL. The Choi′s algorithm had a very high concordance with the GEP results (87%). Therefore, FoxP1 is useful in subclassification of DLBCL and a high cutoff (≥80%) for FoxP1 is needed to achieve high specificity for the ABC subtype.

品質


IVD

IVD

IVD

RUO

関連事項

FoxP1 Positive Control Slides, Product No. 350S, are available for immunohistochemistry (formalin-fixed, paraffin-embedded sections).

物理的形状

Solution in Tris Buffer, pH 7.3-7.7, with 1% BSA and <0.1% Sodium Azide

調製ノート

Download the IFU specific to your product lot and formatNote: This requires a keycode which can be found on your packaging or product label.

その他情報

For Technical Service please contact: 800-665-7284 or email: service@cellmarque.com

法的情報

Cell Marque is a trademark of Merck KGaA, Darmstadt, Germany

適切な製品が見つかりませんか。  

製品選択ツール.をお試しください


最新バージョンのいずれかを選択してください:

試験成績書(COA)

Lot/Batch Number

申し訳ございませんが、現在この製品のCOAをオンラインで入手できません。

サポートが必要な場合は、お問い合わせください カスタマーサポート

以前この製品を購入いただいたことがある場合

文書ライブラリで、最近購入した製品の文書を検索できます。

文書ライブラリにアクセスする

Further studies on biosynthesis of erythropoietin.
R Bandyopadhyay et al.
Indian journal of biochemistry & biophysics, 18(4), 241-244 (1981-08-01)
Andreas Rosenwald et al.
The New England journal of medicine, 346(25), 1937-1947 (2002-06-21)
The survival of patients with diffuse large-B-cell lymphoma after chemotherapy is influenced by molecular features of the tumors. We used the gene-expression profiles of these lymphomas to develop a molecular predictor of survival. Biopsy samples of diffuse large-B-cell lymphoma from
Paul N Meyer et al.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 29(2), 200-207 (2010-12-08)
Patients with diffuse large B-cell lymphoma (DLBCL) can be divided into prognostic groups based on the cell of origin of the tumor as determined by microarray analysis. Various immunohistochemical algorithms have been developed to replicate these microarray results and/or stratify
Swerdlow, SH et al. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. Geneva: World Health Organization; 2008.
WHO Classification of Tumours of Haematopoietic and Lymphoid Tissue (2008)
H Hagberg et al.
Annals of oncology : official journal of the European Society for Medical Oncology, 17 Suppl 4, iv31-iv32 (2006-05-17)
The multicentre phase III CORAL study aims to guide choice of salvage chemotherapy in diffuse large B-cell lymphoma (DLBCL) and assess the role of rituximab maintenance after autologous stem cell transplantation (ASCT). Patients are first randomised between ICE (ifosfamide, carboplatin

ライフサイエンス、有機合成、材料科学、クロマトグラフィー、分析など、あらゆる分野の研究に経験のあるメンバーがおります。.

製品に関するお問い合わせはこちら(テクニカルサービス)